Bristol-Myers Opdivo Did Not Meet Trial Primary Endpoint
Source: BFW (Bloomberg First Word)
Tickers
BMY US (Bristol-Myers Squibb Co)
4528 JP (Ono Pharmaceutical Co Ltd)
To de-activate this alert, click here
UUID: 7947283
(Bloomberg) -- Bristol-Myers Squibb says Opdivo did not meet trial primary endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer whose tumors expressed PD-L1 at ≥ 5%. Link to Statement:Link
Alert: HALISTERSource: BFW (Bloomberg First Word)
Tickers
BMY US (Bristol-Myers Squibb Co)
4528 JP (Ono Pharmaceutical Co Ltd)
To de-activate this alert, click here
UUID: 7947283